Proteus has announced that it has been granted U.S. Patent No. 6,951,719 for L-Shuffling™, a gene shuffling technology developed by Proteus to generate and optimize proteins for commercial product applications.
This L-Shuffling™ recombination-based protein engineering technology dramatically accelerates the development of new or improved products and processes.
L-Shuffling™'s growing list of applications include developing therapeutic proteins, industrial biocatalysts and agricultural traits optimization.
The new patent broadly covers Proteus in vitro gene shuffling recombination methods in a variety of embodiments, and contains multiple claims covering ligation-mediated in vitro recombination methods.
“Getting the protein you have been dreaming of is what L-Shuffling™ provides,” said Daniel Dupret, President and CEO of Proteus. “The issuance of this new patent reinforces Proteus leadership in this field of biotechnology.”